BL
MCID: BRK010
MIFTS: 66

Burkitt Lymphoma (BL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Burkitt Lymphoma

MalaCards integrated aliases for Burkitt Lymphoma:

Name: Burkitt Lymphoma 57 12 20 58 73 36 29 13 54 6 44 15 37 39 71 32
Burkitt's Lymphoma 12 74 20 15
Bl 57 20 73
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 58
Lymphoma, Small Noncleaved-Cell 71
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt Lymphoma, Somatic 57
Burkitts Lymphoma 17
Burkitt's Tumor 12
Burkitt Tumor 73

Characteristics:

Orphanet epidemiological data:

58
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation
isolated cases

Miscellaneous:
accounts for 30-50% of lymphomas in children
accounts for 1-2% of lymphomas in adults
three distinct clinical forms - endemic (equatorial africa), sporadic, and immunodeficiency-associated (e.g., hiv infection)


HPO:

31
burkitt lymphoma:
Inheritance somatic mutation sporadic


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8584
OMIM® 57 113970
KEGG 36 H00008
ICD9CM 34 200.2
MeSH 44 D002051
NCIt 50 C2912
SNOMED-CT 67 118617000
ICD10 32 C83.7
MESH via Orphanet 45 D002051 D008228
ICD10 via Orphanet 33 C83.7
UMLS via Orphanet 72 C0006413 C0079770
Orphanet 58 ORPHA543
MedGen 41 C0006413
UMLS 71 C0006413 C0079770

Summaries for Burkitt Lymphoma

GARD : 20 Burkitt lymphoma (BL) is a very fast-growing type of cancer. It is a form of B-cell non-Hodgkin's lymphoma. There are 3 recognized forms of BL: Endemic (African) - the most common form, found mainly in central Africa, where it is associated with the Epstein Barr virus (EBV). It is most common in children. This form often manifests as enlargement of the jaw or facial bones. Sporadic - a rarer form, seen in all parts of the world, that often develops in the abdomen with bone marrow involvement. The kidneys, ovaries, breasts or other organs may also be involved. This form commonly affects children and young adults. Immunodeficiency-associated - occurs primarily in people with HIV infection, and less commonly in people with other immunodeficiency disorders or recipients of organ transplants. Signs and symptoms may differ depending on the form of BL and the organs or body systems involved. When it spreads, weakness and fatigue often develop. Lymphoma cells may build up in the lymph nodes and other organs, causing swelling. Central nervous system involvement is possible with all forms of BL, particularly when there is advanced-stage disease. The exact cause of BL is not known. EBV infection appears to play a role in virtually all cases of endemic (African) BL, and a minority of sporadic and immunodeficiency-associated BL. While acquired (not inherited) genetic changes involving the MYC gene and other genes are present within BL cancer cells, it is unclear what causes these genetic changes to occur. Without timely treatment, BL is rapidly fatal. Treatment involves intensive chemotherapy, which includes chemotherapy to the fluid surrounding the brain and spinal cord. The majority of people treated with aggressive therapy achieve long-term remission.

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to lymphoma and lymphoma, hodgkin, classic. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Vindesine and Tenofovir have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are hyperuricemia and abnormality of bone marrow cell morphology

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM® : 57 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1 to 2% of lymphomas in adults (Harris and Horning, 2006). It results from chromosomal translocations that involve the MYC gene (190080) and either the lambda or the kappa light chain immunoglobulin genes (147220, 147200). Burkitt lymphoma is causally related to the Epstein-Barr virus (EBV), although the pathogenetic mechanisms are not clear. (113970) (Updated 05-Mar-2021)

KEGG : 36 Burkitt lymphoma (BL) is a highly aggressive mature B-cell non-Hodgkin's lymphoma consisting of endemic, sporadic, and immunodeficiency-associated variants. Endemic BL (eBL) affects children and young adults in Africa and some other geographical areas and carries Epstein-Barr virus (EBV) in more than 95% of cases. In contrast, sporadic BL (sBL) among adolescents in Europe and North America are mostly EBV-negative. A third type of BL is associated with HIV-infection in adults. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of BL that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Many BL carry point mutation in the p53 tumor suppressor gene or other defects in the p14ARF-MDM2-p53 pathway, and inactivation of the p16INK4a gene by promoter methylation or homozygous deletion. This indicates that disruption of both the pRb and p53 tumor suppressor pathways is critical for BL development.

UniProtKB/Swiss-Prot : 73 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Wikipedia : 74 Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal... more...

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.9 TCL1A PVT1 PMS2 PAX5 MYC CXCR5
2 lymphoma, hodgkin, classic 32.3 PVT1 PAX5 MIR155 BCL6
3 b-cell lymphoma 32.2 TP53COR1 TCL1A PVT1 PAX5 MYC MIR155
4 lymphoma, non-hodgkin, familial 32.1 TCL1A PAX5 MYC MIR155 MIR143 CXCR5
5 diffuse large b-cell lymphoma 31.9 PAX5 MYC MIR155 MIR145 MIR143 MIR127
6 b-cell non-hodgkin lymphoma 31.7 BCL7A BCL6
7 leukemia, acute lymphoblastic 31.5 TCL1A PAX5 MYC MIRLET7C MIR155 CXCR5
8 acquired immunodeficiency syndrome 31.5 NEAT1 MYC CXCR5 BCL6
9 follicular lymphoma 31.5 MYC MIR155 CXCR5 BCL6 AICDA
10 mature b-cell neoplasm 31.3 PVT1 PAX5 MYC MIR155 BCL6 AICDA
11 b-lymphoblastic leukemia/lymphoma 31.2 PAX5 MYC CXCR5
12 pediatric lymphoma 31.2 TCL1A MYC BCL6
13 plasmacytoma 31.2 PVT1 PAX5 MYC AICDA
14 mantle cell lymphoma 31.1 TCL1A PAX5 MYC MIR155 CXCR5 BCL6
15 plasmablastic lymphoma 31.0 MYC BCL6
16 nasopharyngeal carcinoma 31.0 PVT1 NEAT1 MYC MIR34B MIR143
17 central nervous system lymphoma 31.0 PAX5 MYC CXCR5 BCL6
18 primary central nervous system lymphoma 31.0 PAX5 CXCR5 BCL6
19 lymphoma, mucosa-associated lymphoid type 30.8 PAX5 MYC CXCR5 BCL6 AICDA
20 lymphoma aids related 30.8 TCL1A MYC BCL6
21 composite lymphoma 30.7 PAX5 BCL6
22 splenic marginal zone lymphoma 30.7 PAX5 BCL6 AICDA
23 reticulosarcoma 30.7 PAX5 MYC BCL6
24 appendix lymphoma 30.7 MYC BCL6
25 leukemia, chronic lymphocytic 30.6 TP53COR1 TCL1A PAX5 NEAT1 MYC MIR155
26 retinitis pigmentosa 11 30.6 PVT1 NEAT1 MYC
27 adult lymphoma 30.6 MYC BCL6
28 gallbladder lymphoma 30.4 PAX5 BCL6
29 myeloma, multiple 30.4 PVT1 MYC MIR145 BCL6
30 lymphatic system disease 30.4 MYC MIR155 MIR145 MIR143 MIR127 BCL6
31 hematologic cancer 30.4 PVT1 PAX5 MIR155 MIR145 MIR143 MIR127
32 intestinal benign neoplasm 30.4 PMS2 MYC MIR145 MIR143
33 intestinal disease 30.4 MIR155 MIR145 MIR143 MIR127 BCL6
34 leukemia, acute myeloid 30.4 PAX5 MYC MIRLET7C MIR34B MIR155 MIR127
35 acute promyelocytic leukemia 30.3 PVT1 NEAT1 MYC MIRLET7C BCL6
36 nervous system disease 30.2 MYC MIR34B MIR155 MIR145 MIR143 MIR127
37 pancreatic cancer 30.1 PVT1 NEAT1 MYC MIR34B MIR155 MIR145
38 ovarian cancer 29.7 PVT1 PMS2 NEAT1 MYC MIRLET7C MIR34B
39 hepatocellular carcinoma 29.3 TP53COR1 PVT1 NEAT1 MYC MIRLET7C MIR155
40 leukemia, acute lymphoblastic 3 11.2
41 paranasal sinus lymphoma 10.7 PAX5 MYC BCL6
42 primary mediastinal b-cell lymphoma 10.6 TCL1A MIR155 BCL6 AICDA
43 intraocular lymphoma 10.6 PAX5 CXCR5 BCL6
44 central nervous system hematologic cancer 10.6 PAX5 MYC BCL6
45 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.6 CXCR5 BCL6
46 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 MYC BCL6
47 immunodeficiency with hyper-igm, type 2 10.6 PAX5 BCL6 AICDA
48 lung lymphoma 10.6 PAX5 BCL6
49 autosomal dominant non-syndromic intellectual disability 10.6 MYC BCL7C BCL6 AICDA
50 eye lymphoma 10.6 CXCR5 BCL6

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Human phenotypes related to Burkitt Lymphoma:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperuricemia 58 31 frequent (33%) Frequent (79-30%) HP:0002149
2 abnormality of bone marrow cell morphology 58 31 frequent (33%) Frequent (79-30%) HP:0005561
3 neoplasm of the oral cavity 58 31 frequent (33%) Frequent (79-30%) HP:0100649
4 increased lactate dehydrogenase level 31 frequent (33%) HP:0025435
5 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
6 abnormality of the ovary 58 31 occasional (7.5%) Occasional (29-5%) HP:0000137
7 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
8 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
9 abnormality of the spleen 58 31 occasional (7.5%) Occasional (29-5%) HP:0001743
10 intestinal obstruction 58 31 occasional (7.5%) Occasional (29-5%) HP:0005214
11 abnormality of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0001392
12 abnormality of the pancreas 58 31 occasional (7.5%) Occasional (29-5%) HP:0001732
13 abnormality of the lymph nodes 58 31 occasional (7.5%) Occasional (29-5%) HP:0002733
14 decreased proportion of cd4-positive helper t cells 31 occasional (7.5%) HP:0005407
15 immunodeficiency 31 HP:0002721
16 increased lactate dehydrogenase activity 58 Frequent (79-30%)
17 decreased proportion of cd4-positive t cells 58 Occasional (29-5%)
18 burkitt lymphoma 31 HP:0030080

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
burkitt lymphoma (b-cell lymphoma)
jaw and kidney tumor (endemic form)
ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
abdominal tumors (immunodeficiency-associated form)
monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
more
Laboratory Abnormalities:
elevated lactate dehydrogenase
elevated uric acid
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin lambda light chain (, 22q11.2) locus
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin kappa light chain (, 2p12) locus
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin heavy chain (, 14q32) locus

Clinical features from OMIM®:

113970 (Updated 05-Mar-2021)

Drugs & Therapeutics for Burkitt Lymphoma

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
2
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
3
tannic acid Approved Phase 3 1401-55-4
4
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
5
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
6 Cyclosporins Phase 3
7
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
8
Teniposide Approved Phase 2 29767-20-2 34698
9
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
10
Iodine Approved, Investigational Phase 2 7553-56-2 807
11
alemtuzumab Approved, Investigational Phase 2 216503-57-0
12
Bevacizumab Approved, Investigational Phase 2 216974-75-3
13
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
14
Ondansetron Approved Phase 2 99614-02-5 4595
15 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
16
Acetaminophen Approved Phase 2 103-90-2 1983
17
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
18
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
19
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
20
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
21
Promethazine Approved, Investigational Phase 2 60-87-7 4927
22
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
23
Etoposide Approved Phase 2 33419-42-0 36462
24
Ichthammol Approved Phase 2 8029-68-3
25
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578
26
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
27
ofatumumab Approved Phase 2 679818-59-8 6918251
28
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
29
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
30
nivolumab Approved Phase 2 946414-94-4
31
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
32
Melphalan Approved Phase 2 148-82-3 4053 460612
33
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
34
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
35
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
36
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
37
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
38
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
39
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
40
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Mycophenolic acid Approved Phase 2 24280-93-1 446541
43
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
44
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
45
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
48
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
49
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
50
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 216)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
4 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
5 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
6 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101) Completed NCT01597778 Phase 3
7 Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma Unknown status NCT01516593 Phase 2 Induction Phase;Consolidation Phase (on day +50);Intensification phase;BEAM conditioning
8 Phase II Trial of CLAG-M in Relapsed ALL Unknown status NCT01513603 Phase 2 CLAG-M;CLAG-M
9 Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) Completed NCT00412243 Phase 1, Phase 2 Clofarabine;Cyclophosphamide
10 Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Completed NCT00669877 Phase 2 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;G-CSF;Cytarabine;Methotrexate
11 Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) Completed NCT00388193 Phase 2 RITUXIMAB
12 Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma Completed NCT00392834 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;liposomal cytarabine;methotrexate;therapeutic hydrocortisone;vincristine sulfate
13 Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia Completed NCT00039130 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;prednisone;vincristine sulfate;Allopurinol
14 Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas Completed NCT00303953 Phase 2 belinostat
15 A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy Completed NCT00057811 Phase 2 doxorubicin hydrochloride;cyclophosphamide;methotrexate;rasburicase;leucovorin calcium;prednisone;methylprednisolone;cytarabine;etoposide;vincristine sulfate;hydrocortisone sodium succinate
16 Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma Completed NCT01290120 Phase 2 Chemotherapy-Rituximab combination
17 Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas Completed NCT00001237 Phase 2 granulocyte-macrophage colony stimulating factor (GM-CSF)
18 A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults Completed NCT01314014 Phase 2 Imexon
19 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
20 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
21 A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01109069 Phase 2 PCI-32765
22 Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II Completed NCT00187161 Phase 2 Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
23 Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma Completed NCT00133991 Phase 2 Cyclophosphamide;Cytarabine;Methotrexate;Prednisone;Hydrocortisone;Vincristine;Leucovorin
24 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
25 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
26 A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation Completed NCT00064246 Phase 1, Phase 2
27 A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas Completed NCT00058019 Phase 2 ixabepilone
28 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
29 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
30 A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma Completed NCT00040690 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
31 Bevacizumab (rhuMab VEGF) (NSC-704865) Therapy for Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma Completed NCT00016094 Phase 2
32 A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine Completed NCT01397825 Phase 1, Phase 2 Alisertib (MLN8237);Rituximab;Vincristine
33 Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia Completed NCT01363128 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Methotrexate;Vincristine Sulfate
34 A Phase II Study of CCI-779 in B-cell Lymphoma and CLL Completed NCT00290472 Phase 2 temsirolimus
35 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
36 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
37 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
38 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
39 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
40 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
41 A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma Completed NCT00392990 Phase 2 Regimen A;Regimen B
42 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
43 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
45 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
46 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
47 A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies Completed NCT01474681 Phase 1, Phase 2
48 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
49 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
50 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cyclophosphamide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

# Genetic test Affiliating Genes
1 Burkitt Lymphoma 29 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

40
B Cells, Bone Marrow, T Cells, Bone, Breast, Liver, Myeloid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 8468)
# Title Authors PMID Year
1
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. 57 6 61
8220424 1993
2
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. 57 61
28562582 2017
3
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. 61 57
23143595 2012
4
The genetic landscape of mutations in Burkitt lymphoma. 57 61
23143597 2012
5
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. 57 61
22885699 2012
6
MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. 54 61 47
18802929 2008
7
Burkitt's lymphoma--the message from microarrays. 61 57
16760450 2006
8
Molecular diagnosis of Burkitt's lymphoma. 61 57
16760443 2006
9
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. 61 57
16760442 2006
10
Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. 61 57
12219084 2002
11
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. 61 57
11118209 2000
12
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. 57 61
10559294 1999
13
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. 61 57
9765461 1998
14
Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. 57 61
2833750 1988
15
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region. 61 57
3116544 1987
16
Familial Burkitt's lymphoma. Association with altered lymphocyte subsets in family members. 61 57
3487979 1986
17
Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. 57 61
3458257 1986
18
In situ hybridization and translocation breakpoint mapping. I. Nonidentical 22q11 breakpoints for the t(9;22) of CML and the t(8;22) of Burkitt lymphoma. 61 57
6467987 1984
19
The discovery of Burkitt's lymphoma. 57 61
6299496 1983
20
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. 57 61
6806672 1982
21
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. 57 61
946170 1976
22
Update on Burkitt Lymphoma. 61 20
27888884 2016
23
B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. 61 47
19530237 2010
24
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 61 47
17892514 2007
25
Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. 61 47
17173072 2007
26
Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. 61 47
16235244 2006
27
High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. 47 61
14695998 2004
28
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. 57
6300885 1983
29
Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C alpha gene from chromosome 12 in two murine plasmacytomas. 57
6960358 1982
30
Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes. 57
6801764 1982
31
The role of gene dosage and genetic transpositions in carcinogenesis. 57
7312030 1981
32
A sarcoma involving the jaws in African children. 57
13628987 1958
33
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. 61 54
19844983 2010
34
Using an automated cell counter to simplify gene expression studies: siRNA knockdown of IL-4 dependent gene expression in Namalwa cells. 54 61
20393449 2010
35
Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. 54 61
20081364 2010
36
c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma. 61 54
19881537 2010
37
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 61 54
20023257 2010
38
To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. 54 61
19874894 2009
39
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. 61 54
20003543 2009
40
Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. 54 61
19880779 2009
41
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 61 54
20079013 2009
42
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 61 54
19734146 2009
43
Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells. 61 54
19557576 2009
44
PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. 61 54
19363465 2009
45
Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. 54 61
19421231 2009
46
[Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody]. 54 61
19698222 2009
47
Activation of mTORC1 signaling pathway in AIDS-related lymphomas. 54 61
19608873 2009
48
Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation. 54 61
19403666 2009
49
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. 61 54
19349957 2009
50
BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. 61 54
19332026 2009

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYC NM_002467.6(MYC):c.214C>T (p.Pro72Ser) SNV Pathogenic 12574 rs28933407 8:128750677-128750677 8:127738431-127738431
2 MYC NM_002467.6(MYC):c.302A>C (p.Asn101Thr) SNV Pathogenic 12575 rs121918683 8:128750765-128750765 8:127738519-127738519
3 MYC NM_002467.6(MYC):c.162G>C (p.Glu54Asp) SNV Pathogenic 12576 rs121918684 8:128750625-128750625 8:127738379-127738379
4 MYC NM_002467.6(MYC):c.220C>G (p.Pro74Ala) SNV Pathogenic 12577 rs121918685 8:128750683-128750683 8:127738437-127738437
5 PMS2 NM_000535.7(PMS2):c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer) Indel Pathogenic 91366 rs267608150 7:6037019-6037024 7:5997388-5997393

Cosmic variations for Burkitt Lymphoma:

9 (show all 27)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102656129 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
2 COSM89046819 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
3 COSM105514140 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
4 COSM94463526 NF2 central nervous system,brain,other,neoplasm c.452A>G p.Y151C 22:29655652-29655652 3
5 COSM102848205 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
6 COSM93474794 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
7 COSM89067962 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
8 COSM105111282 NF2 central nervous system,brain,other,neoplasm c.447+13367A>G p.? 22:29655652-29655652 3
9 COSM95502154 NF2 central nervous system,brain,other,neoplasm c.449A>G p.Y150C 22:29655652-29655652 3
10 COSM92446479 NF2 central nervous system,brain,other,neoplasm c.326A>G p.Y109C 22:29655652-29655652 3
11 COSM90465359 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
12 COSM112752230 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
13 COSM103033757 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
14 COSM103033796 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
15 COSM103034325 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
16 COSM112752272 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
17 COSM90465396 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
18 COSM90466087 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
19 COSM90465733 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
20 COSM112752610 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
21 COSM112752921 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
22 COSM112752563 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
23 COSM90465675 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
24 COSM103034038 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
25 COSM103034000 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
26 COSM93220513 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
27 COSM102860866 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 17456 1 142870000 177000000 Gain RNF115 Burkitt''s lymphoma
2 17457 1 142870000 177000000 Gain BCL9 Burkitt''s lymphoma
3 17458 1 142870000 177000000 Gain LHX4 Burkitt''s lymphoma
4 17459 1 142870000 177000000 Gain PIAS3 Burkitt''s lymphoma
5 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
6 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
7 26526 1 200970000 201360000 Gain LRRN2 Burkitt''s lymphoma
8 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
9 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
10 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
11 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
12 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
13 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
14 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
15 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
16 64462 12 128465362 132449811 Gain Burkitt''s lymphoma
17 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
18 70408 12 61724591 82263925 Gain Burkitt''s lymphoma
19 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
20 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
21 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
22 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
23 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
24 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
25 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
26 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
27 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma
28 75138 13 16000000 114142980 Deletion Burkitt''s lymphoma
29 75160 13 16000000 39500000 Insertion ABCC4 Burkitt''s lymphoma
30 77034 13 39500000 52200000 Deletion Burkitt''s lymphoma
31 79790 13 77800000 100500000 Insertion TBC1D4 Burkitt''s lymphoma
32 80310 13 89580000 96810000 Amplification ABCC4 Burkitt''s lymphoma
33 80311 13 89580000 96810000 Amplification CLDN10 Burkitt''s lymphoma
34 80312 13 89580000 96810000 Amplification DCT Burkitt''s lymphoma
35 80313 13 89580000 96810000 Amplification DNAJC3 Burkitt''s lymphoma
36 80314 13 89580000 96810000 Amplification DZIP1 Burkitt''s lymphoma
37 80315 13 89580000 96810000 Amplification GPC5 Burkitt''s lymphoma
38 80316 13 89580000 96810000 Amplification GPC6 Burkitt''s lymphoma
39 80317 13 89580000 96810000 Amplification GPR180 Burkitt''s lymphoma
40 80318 13 89580000 96810000 Amplification HS6ST3 Burkitt''s lymphoma
41 80319 13 89580000 96810000 Amplification SOX21 Burkitt''s lymphoma
42 80320 13 89580000 96810000 Amplification TGDS Burkitt''s lymphoma
43 80321 13 89580000 96810000 Amplification UGGT2 Burkitt''s lymphoma
44 80322 13 89580000 96810000 Amplification MIR17 Burkitt''s lymphoma
45 80323 13 89580000 96810000 Amplification MIR19A Burkitt''s lymphoma
46 80324 13 89580000 96810000 Amplification MIR19B1 Burkitt''s lymphoma
47 80352 13 90362259 90843579 Gain Burkitt''s lymphoma
48 80683 13 96008275 114142980 Loss Burkitt''s lymphoma
49 80791 13 97790000 97850000 Gain FARP1 Burkitt''s lymphoma
50 84296 14 26520000 43840000 Loss FANCM Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.14 PAX5 CXCR5 BCL6 AICDA
2 11.59 MYC MIRLET7C MIR34B MIR155 MIR145 MIR143
3 11.25 PAX5 CXCR5 BCL6
4 11.03 MYC MIR34B MIR145
5 10.58 MYC MIRLET7C MIR34B

GO Terms for Burkitt Lymphoma

Biological processes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of macrophage activation GO:0043032 9.48 MIR155 MIR145
2 regulation of smooth muscle contraction GO:0006940 9.46 MIR145 MIR143
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.43 PMS2 AICDA
4 positive regulation of connective tissue replacement GO:1905205 9.4 MIR34B MIR155
5 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.37 MIR34B MIR155
6 angiotensin-activated signaling pathway GO:0038166 9.32 MIR145 MIR143
7 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR145 MIR143
8 gene silencing by miRNA GO:0035195 9.17 NEAT1 MIRLET7C MIR34B MIR155 MIR145 MIR143
9 regulation of phenotypic switching GO:1900239 9.16 MIR145 MIR143
10 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR145 MIR143

Molecular functions related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIRLET7C MIR34B MIR155 MIR145 MIR143

Sources for Burkitt Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....